Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-994 extension and randomized withdrawal study in adults with narcolepsy type 1
2021-000251-39Phase 2Completed
- Sponsor
- Takeda
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of firazorexton in narcolepsy type 1 (NT1) (3 arms), sponsored by Takeda. Primary endpoint: Subjects with at least 1 treatment-emergent adverse event during the active drug extension period. Started Apr 2021; status: completed.
02
Drugs
firazorexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on 2021-000251-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000251-39.